Osteocalcin (human)

OC(C(C[C@H](NC([C@@H](NC([C@@H]1CCCN1C([C@H](CC(O)=O)NC([C@@H]2CCCN2C([C@H](CC3=CC=C(C=C3)O)NC([C@@H]4CCCN4C([C@@H](NC([C@@H]5CCCN5C([C@H](C)NC(CNC([C@@H](NC([C@H](CC6=CNC7=C6C=CC=C7)NC([C@@H](NC([C@H](CC8=CC=C(C=C8)O)NC([C@@H](NC([C@H](CC9=CC=C(C=C9)O)N[H])=O)CC(C)C)=O)=O)CCC(N)=O)=O)=O)CC(C)C)=O)=O)=O)=O)C(C)C)=O)=O)=O)=O)=O)=O)CC(C)C)=O)C(N%10CCC[C@H]%10C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%11=CN=CN%11)C(N[C@]([H])(C(NCC(N[C@@H](CC%12=CC=CC=C%12)C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC%13=CC=C(C=C%13)O)C(N[C@H](C(N[C@H](C(N[C@@H](CC%14=CC=CC=C%14)C(N[C@@H](CC%15=CC=C(C=C%15)O)C(NCC(N%16CCC[C@H]%16C(N[C@H](C(O)=O)C(C)C)=O)=O)=O)=O)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)=O)=O)[C@@H](C)CC)=O)=O)=O)=O)CC(C)C)=O)CCC(O)=O)=O)=O)N%17)C(N[C@H](C(N[C@H](C(N[C@H](C(N%18CCC[C@H]%18C(N[C@@H](CC(O)=O)C%17=O)=O)=O)CC(N)=O)=O)CC(C)C)=O)CC(C(O)=O)C(O)=O)=O)=O)C(C)C)=O)CC(C(O)=O)C(O)=O)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)=O)C(O)=O)=O

[1]Kuronen I, et al. Production of monoclonal and polyclonal antibodies against human osteocalcin sequences and development of a two-site ELISA for intact human osteocalcin. J Immunol Methods. 1993 Aug 9;163 (2) :233-40.|[2]Mundy GR, et al. Chemotactic activity of the gamma-carboxyglutamic acid containing protein in bone. Calcif Tissue Int. 1983;35 (2) :164-8.|[3]Colford JW, et al. Immunoradiometric assay for intact human osteocalcin (1-49) without cross-reactivity to breakdown products. Clin Chem. 1999 Apr;45 (4) :526-31.